Royalty Pharma buys remaining royalty interest in Roche drug Evrysdi
Source: SeekingAlpha
2025-12-29 17:13:13 ET
More on Royalty Pharma
- Royalty Pharma plc (RPRX) Presents at Evercore 8th Annual Healthcare Conference Transcript
- Royalty Pharma plc (RPRX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
- Royalty Pharma: Guidance Raised Again, Platform Strength Intact -- Buy Reiterated
- Royalty Pharma buys royalty interest in Nuvalent cancer drugs for up to $315 mln
- Royalty Pharma raises 2025 top line guidance to $3.2B–$3.25B amid strong portfolio expansion
Read the full article on Seeking Alpha
For further details see:
Royalty Pharma buys remaining royalty interest in Roche drug Evrysdi
PTC Therapeutics Inc.
NASDAQ: PTCT
PTCT Trading
-6.11% G/L:
$65.76 Last:
236,092 Volume:
$67.91 Open:
PTCT Latest News
March 03, 2026 10:11:53 am
Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing
February 19, 2026 04:01:00 pm
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
PTCT Stock Data
$5,800,830,036
75,872,448
1.06%
134
N/A
Biotechnology & Life Sciences
Healthcare
US
Warren
